Florida’s experimental Alzheimer’s program costs approximately $3,300 per month—roughly a quarter of what traditional memory care facilities charge—and uses an intensive protocol called ReCODE (Reversal of Cognitive Decline) developed by California neurologist Dr. Dale Bredesen. The program works through a comprehensive initial evaluation that includes blood work, genetic testing, cognitive testing, and sleep studies, designed to identify biological markers and risk factors specific to each patient.
One patient who participated in clinical trials received approximately $30,000 worth of treatments over nine months, including hyperbaric chamber sessions alongside personalized medications and lifestyle modifications. This approach represents a significant departure from conventional Alzheimer’s care, which typically focuses on managing symptoms rather than targeting underlying biological causes. Florida has become a hub for this experimental treatment, with 17 memory clinics throughout the state offering testing, diagnosis, and treatment protocols as part of the state’s broader research initiative. The accessibility and lower cost compared to traditional facilities have made the program attractive to families seeking alternatives, though what the treatment actually delivers remains an open question.
Table of Contents
- How Much Does the ReCODE Protocol Really Cost?
- What the Initial Evaluation Actually Covers
- Dr. Dale Bredesen’s Protocol and the Experimental Status
- Where and How to Access the ReCODE Protocol in Florida
- What the Program Cannot Do and Important Limitations
- Florida’s Major Research Investment Behind the Program
- What Treatment Actually Looks Like and What to Expect
How Much Does the ReCODE Protocol Really Cost?
The monthly cost of approximately $3,300 reflects the intensive testing, specialist consultations, and ongoing monitoring required in the first months of treatment. This figure becomes most meaningful when compared to traditional memory care facilities, which can exceed $14,000 monthly for residential placement. The program’s lower cost structure doesn’t mean the treatment is simpler; rather, it reflects the shift from residential facility fees to outpatient medical protocols, allowing patients to receive care while remaining at home. The $30,000 example over nine months provides a concrete picture of what a moderately intensive treatment course looks like.
This included multiple hyperbaric oxygen therapy sessions—sessions that can cost $100 to $200 each—plus blood work, cognitive assessments, sleep studies, and medications tailored to each patient’s test results. For some families, the total cost remains substantial; for others, especially those who would otherwise need residential care, the expense represents a significant savings over years of treatment. It’s important to note that costs vary based on how aggressively the protocol is pursued and which specific interventions are recommended based on individual test results. Some patients may require more frequent appointments, additional testing, or more expensive treatments like hyperbaric oxygen therapy, while others might follow a simpler medication and lifestyle adjustment plan. Insurance coverage for these experimental protocols remains inconsistent and varies by provider.
What the Initial Evaluation Actually Covers
The comprehensive evaluation that launches the ReCODE protocol is substantially more detailed than a standard neurology visit. Blood work screens for inflammation markers, cholesterol, hormones, and metabolic factors. Genetic testing identifies whether a patient carries the APOE4 gene, strongly associated with Alzheimer’s risk. Cognitive testing objectively measures memory, language, and processing speed—establishing a baseline against which later improvements can be measured. Sleep studies assess sleep quality and apnea, factors increasingly recognized as important to cognitive decline.
This multi-faceted assessment approach reflects Dr. Bredesen’s underlying theory: Alzheimer’s isn’t a single disease but a complex response to multiple biological stressors that can include inflammation, hormonal imbalance, sleep disruption, vitamin deficiencies, insulin resistance, and cardiovascular issues. By identifying which factors are present in each individual, the protocol aims to create a personalized treatment plan rather than using a one-size-fits-all approach. A critical limitation: The ReCODE protocol is not advertised as a cure, and marketing materials emphasize “reversal of cognitive decline” rather than restoration to original cognitive function. Some patients have reported cognitive improvement; others have seen stabilization rather than reversal; others have continued to decline despite treatment. The clinical evidence remains preliminary, and no major pharmaceutical companies have validated these approaches through the large, rigorous trials that typically establish medical legitimacy.
Dr. Dale Bredesen’s Protocol and the Experimental Status
Dr. Bredesen developed the ReCODE protocol based on the hypothesis that targeting multiple underlying biological factors might slow or reverse cognitive decline in early Alzheimer’s disease and mild cognitive impairment. The protocol combines prescription medications (like metformin for insulin resistance or hormonal treatments), supplements, dietary changes (typically a modified Mediterranean or ketogenic diet), sleep optimization, exercise, and cognitive training. The experimental designation means these treatments haven’t undergone the rigorous, large-scale clinical trials required for FDA approval as Alzheimer’s treatments.
Smaller studies and case reports suggest some patients benefit, but the evidence base remains limited compared to established Alzheimer’s medications. Patients considering the protocol should understand they’re participating in something more akin to a structured research program than an established medical treatment with proven efficacy. Florida has become a natural hub for this protocol partly because the state has invested heavily in Alzheimer’s research infrastructure. The involvement of major institutions and the state’s research funding create a framework within which clinics can operate, but this doesn’t provide the same regulatory assurance as FDA approval. Families should ask whether clinics are collecting outcomes data, how they define success, and whether they provide honest assessments of who is likely to benefit.
Where and How to Access the ReCODE Protocol in Florida
Seventeen memory clinics throughout Florida now offer the ReCODE protocol and related services, providing testing, diagnosis, treatment, and research support at regional memory disorder centers. These clinics serve as entry points for patients who want to explore the protocol without necessarily relocating or moving to a residential facility. The availability across multiple regions means families in different parts of Florida have access rather than needing to travel to a single specialized center. When a patient enrolls, the typical pathway involves the comprehensive initial evaluation, followed by a team meeting where results are discussed and a personalized treatment plan is created.
Patients then return for regular monitoring appointments to assess progress, adjust medications or supplements, review lifestyle changes, and repeat cognitive testing at intervals to measure whether decline is slowing, stabilizing, or reversing. The frequency of visits and length of the protocol varies; some patients commit to intensive treatment for 12 to 18 months, while others pursue longer-term care. One practical consideration: These clinics function as medical practices, not facilities, so patients and families are responsible for implementing the treatment plan—taking medications, making dietary changes, maintaining sleep schedules, and completing cognitive exercises. Unlike residential memory care, where facility staff manages daily routines, the ReCODE protocol requires active engagement and commitment from the patient and caregiving family. For some families, this independence is an advantage; for others, especially as cognitive decline progresses, it becomes burdensome.
What the Program Cannot Do and Important Limitations
The protocol is most effective in early stages of cognitive decline—mild cognitive impairment or very early Alzheimer’s—and becomes less viable as dementia advances and patients lose the ability to self-manage care or follow complex treatment regimens. Patients with moderate to advanced dementia generally cannot maintain the level of active participation the protocol requires, and the program is not positioned as a residential care solution for severely declining individuals. Financial commitment is substantial even at the lower monthly rate. Treatment typically extends months to years, and families bear the cost for any services not covered by insurance. Some insurance plans cover cognitive testing and some medications; fewer cover supplements, hyperbaric oxygen therapy, or extended specialist appointments.
Additionally, the program’s effectiveness remains individual and unpredictable; not all patients experience cognitive improvement, and some experience no measurable benefit despite completing the protocol. Another significant limitation is the lack of long-term data. The protocol has been used clinically for roughly a decade, but sustained outcome data beyond a few years remains limited. Families should be cautious of any clinic that promises reversal or cure, as these claims exceed the evidence available. Honest practitioners describe the goal as slowing decline, stabilizing cognition, or, in favorable cases, demonstrating measurable improvement—but always conditional on the patient’s specific circumstances and biology.
Florida’s Major Research Investment Behind the Program
In May 2026, Florida’s Surgeon General and Secretary announced $4.2 million in new Alzheimer’s research grants, part of the state’s broader commitment to advancing innovation in cognitive decline treatment. This recent funding supplements over $35 million invested in Alzheimer’s research since 2018, representing a substantial state-level commitment to understanding and treating the disease. The research investments support 164 research projects, involve 126 researchers, and span 13 institutions across Florida.
This research infrastructure provides the clinical and scientific foundation within which programs like ReCODE operate. University hospitals, memory disorder centers, and regional clinics participate in funded research protocols that generate the evidence used to refine treatment approaches. Patients who access the ReCODE protocol at these clinics often contribute to ongoing research studies, meaning their participation feeds back into the knowledge base that informs future treatment refinements. For some families, knowing their participation advances the field provides additional purpose beyond immediate personal benefit.
What Treatment Actually Looks Like and What to Expect
A patient diagnosed with early Alzheimer’s or mild cognitive impairment might begin with the comprehensive evaluation: blood draws at a lab, a full neuropsychological testing session lasting several hours, a sleep study at home or in a clinic, and a consultation with a specialist who reviews all results and explains the findings. The assessment produces a detailed report identifying specific biological abnormalities—elevated inflammation markers, vitamin B12 deficiency, apolipoprotein E4 genotype, sleep apnea, insulin resistance—each of which then becomes a target for intervention. Treatment might include prescription medications (such as metformin for insulin resistance or thyroid replacement if hypothyroidism is present), a regimen of supplements tailored to the identified deficiencies, dietary modifications, a structured exercise program, cognitive training activities, and recommendations for sleep optimization. Some patients undergo hyperbaric oxygen therapy, where they breathe 95% oxygen in a pressurized chamber for approximately two hours per session, typically once or twice weekly for a defined course.
Others may add medications like intranasal insulin or hormonal treatments depending on test results. The patient or family manages these interventions over weeks and months, with periodic clinic visits to assess adherence and progress, adjust the plan, and repeat testing to measure changes in cognition or biomarkers. The program doesn’t work in isolation; successful patients typically combine the protocol with strong social engagement, continued learning, physical activity, and management of cardiovascular risk factors. These elements complement the medical protocol rather than replacing it. Families entering the program should anticipate significant time commitment, coordination of multiple appointments and treatments, and responsibility for sustained adherence to a complex medical plan.
